Could Jinfukang alleviate the chemotherapy-related adverse effects in non-small cell lung cancer patients?: A protocol for a double-blind, randomized controlled trial

BACKGROUND: Lung cancer is the main cause of cancer-related death in the world, and non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers. Cisplatin and its derivatives are the first-line chemotherapeutic drugs for patients with advanced lung cancer, but the chemother...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Xing, Wang, Wenmin, Wang, Gefei, Liu, Shenghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
3800
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8284706/
https://www.ncbi.nlm.nih.gov/pubmed/34260519
http://dx.doi.org/10.1097/MD.0000000000025002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8284706/
https://www.ncbi.nlm.nih.gov/pubmed/34260519
http://dx.doi.org/10.1097/MD.0000000000025002

Ejemplares similares